- $384.71m
- $317.34m
- $160.95m
- 98
- 62
- 87
- 96
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 20.71 | ||
PEG Ratio (f) | 1.16 | ||
EPS Growth (f) | 21.75% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.48 | ||
Price to Tang. Book | 3.02 | ||
Price to Free Cashflow | 10.44 | ||
Price to Sales | 2.39 | ||
EV to EBITDA | 12.11 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 6.21% | ||
Return on Equity | 5.74% | ||
Operating Margin | 12.46% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 133.25 | 103.64 | 129.34 | 142.52 | 160.95 | 179.87 | 196.49 | 4.82% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -29.89 | n/a | n/a | n/a | +62.07 | +19.11 | +26.51 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Directors
- Lilach Asher Topilsky CHM
- Amir London CEO (47)
- David Tsur VCH (71)
- Chaime Orlev CFO (46)
- Ruth Wolfson SVP (69)
- Barak Bashari VOP (51)
- Shani Dotan VPR (42)
- Yael Brenner VPR (53)
- Orit Pinchuk VPR (51)
- Eran Schenker VPR (53)
- Michal Stein VPR
- Pnina Strauss VPR (41)
- Naveh Tov VPR
- Michal Ayalon VRD
- Eitan Kyiet VBD
- Michael Berelowitz DRC (76)
- Jonathan Hahn DRC (33)
- Itzhak Krinsky DRC
- Gwen Melincoff DRC (69)
- Leon Recanati DRC (73)
- Shmuel Rubinstein DRC (79)
- Ari Shamiss DRC
- Estery Giloz-Ran IND (45)
- Abraham Havron IND (73)
- Tuvia Shoham IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 13th, 1990
- Public Since
- August 1st, 2005
- No. of Employees
- 374
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market
- Shares in Issue
- 57,505,031

- Address
- 2 Holtzman St., Science Park, REHOVOT, 7670402
- Web
- https://www.kamada.com/
- Phone
- +972 89406472
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for KMDA
Q2 2025 Kamada Ltd Earnings Release
Similar to KMDA
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 21:31 UTC, shares in Kamada are trading at $6.69. This share price information is delayed by 15 minutes.
Shares in Kamada last closed at $6.69 and the price had moved by +28.65% over the past 365 days. In terms of relative price strength the Kamada share price has outperformed the S&P500 Index by +18.75% over the past year.
The overall consensus recommendation for Kamada is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Kamada dividend yield is 2.99% based on the trailing twelve month period.
Last year, Kamada paid a total dividend of $0.20, and it currently has a trailing dividend yield of 2.99%. We do not have any data on when Kamada is to next pay dividends.
We do not have data on when Kamada is to next pay dividends. The historic dividend yield on Kamada shares is currently 2.99%.
To buy shares in Kamada you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.69, shares in Kamada had a market capitalisation of $384.71m.
Here are the trading details for Kamada:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KMDA
Based on an overall assessment of its quality, value and momentum Kamada is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kamada is $14.75. That is 120.44% above the last closing price of $6.69.
Analysts covering Kamada currently have a consensus Earnings Per Share (EPS) forecast of $0.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kamada. Over the past six months, its share price has outperformed the S&P500 Index by +33.55%.
As of the last closing price of $6.69, shares in Kamada were trading +8.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kamada PE ratio based on its reported earnings over the past 12 months is 20.71. The shares last closed at $6.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kamada's management team is headed by:
- Lilach Asher Topilsky - CHM
- Amir London - CEO
- David Tsur - VCH
- Chaime Orlev - CFO
- Ruth Wolfson - SVP
- Barak Bashari - VOP
- Shani Dotan - VPR
- Yael Brenner - VPR
- Orit Pinchuk - VPR
- Eran Schenker - VPR
- Michal Stein - VPR
- Pnina Strauss - VPR
- Naveh Tov - VPR
- Michal Ayalon - VRD
- Eitan Kyiet - VBD
- Michael Berelowitz - DRC
- Jonathan Hahn - DRC
- Itzhak Krinsky - DRC
- Gwen Melincoff - DRC
- Leon Recanati - DRC
- Shmuel Rubinstein - DRC
- Ari Shamiss - DRC
- Estery Giloz-Ran - IND
- Abraham Havron - IND
- Tuvia Shoham - IND